

CURRICULUM VITAE

ROBIN JAMES STORER

BSC (HONS), PHD (MEDICINE), MRACI, CCHEM

**FOR CHULALONGKORN UNIVERSITY
FACULTY OF MEDICINE**

07 SEPTEMBER 2016



Professional Address

Robin James Storer, PhD

Assistant Professor

Department of Physiology, Faculty of Medicine

Chulalongkorn University

1873 Rama 4 Road, Pathumwan

Bangkok 10330, Thailand

Telephone: 02-256-4455 Extn. 13

(Khun Rungrat Chaosunngam, Research Affairs)

Fax: 02-256-4493 Extn. 17

e-mail: james.s@chula.ac.th

RESEARCH AND PROFESSIONAL EXPERIENCE

PRINCIPAL POSITIONS HELD

Assistant Professor, Faculty of Medicine, Chulalongkorn University, Bangkok

2012–2018+

Department of Physiology

- Assistant Professor in developing a research and teaching program for the Faculty of Medicine at Chulalongkorn University to investigate the pathophysiology and pharmacology of primary head pain. Coordinating with other faculty and research affairs to establish a Centre for excellence in Neuroscience. Teaching scientific publication, writing, and presentation
- Coeditor, *Asian Biomedicine*, an international journal publishing peer-reviewed contributions regarding experimental and clinical aspects of biomedical sciences, with an editorial team including Editor-in-chief Professor Chitr Sitthi-amorn, MD, Managing editor Khun Sunitra Pakinsee, and co-editors Professor Henry Wilde, MD, FACP, and Associate Professor Alain Jacquet, PhD, and Associate Professor Issarang Nuchprayoon, MD, Professor Weerapan Khovidhunkit, MD, PhD, and Dr Cameron Hurst, PhD. I have rewritten the Guide for Authors of *Asian Biomedicine* and updated the publication ethics and policies, co-authored 8 editorials, screened more than 1000 manuscripts, and reviewed more than 370, bringing at least 300 manuscripts to publication

Assistant Professor, Department of Neurology, University of California, San Francisco

2007–2012

School of Medicine, Appointed Faculty Rank Step III (2007) promoted to Step IV (2009)

- Assistant to Peter J. Goadsby, M.D., Ph.D., D.Sc., Principle Investigator, in establishing new laboratories and a research and teaching program at UCSF to investigate the pathophysiology and pharmacology of primary head pain for the Sandler Foundation

Senior Research Fellow, Institute of Neurology, University College London

1998–2007

Headache Group, Department of Headache, Brain Injury & Rehabilitation

Institute of Neurology and National Hospital Neurology & Neurosurgery

Queen Square, London WC1N 3BG, United Kingdom

- Senior Research Fellow and teaching assistant with Professor Peter J. Goadsby investigating the pathophysiology and pharmacology of primary head pain in collaboration with pharmaceutical companies including Boehringer Ingelheim Pharma KG, Johnson & Johnson Pharmaceutical Research & Development, and Amgen Inc

Research Fellow, Institute of Neurology, University College London

1996–1998

Headache Group, Department of Clinical Neurology

Institute of Neurology and National Hospital Neurology & Neurosurgery

- Research Fellow and laboratory instructor with Professor Peter J. Goadsby investigating the pathophysiology and pharmacology of primary head pain such as in migraine in collaboration with pharmaceutical companies including GlaxoWellcome (later GlaxoSmithKline)

Medical Research Fellow, Prince Henry Hospital, Institute of Neurological Sciences 1994–1996

University of New South Wales, Sydney

Postdoctoral Fellowship with Peter J. Goadsby, Reader in Clinical Neurology

- Developed a highly complex technique (microiontophoresis) allowing the *in vivo* CNS neuropharmacological investigation of anti-migraine drugs in collaboration with pharmaceutical companies including Wellcome (later GlaxoWellcome)

Scientific Research Officer, University of Adelaide, Department of Paediatrics 1986–1988

Women's & Children's Hospital, South Australia

- Synthesis of bioimmunoconjugate anticancer drugs, protein purification, enzymology

OTHER POSITIONS HELD CONCURRENTLY

Consultant, Amgen Inc., Veterans Boulevard, San Francisco, California 2011

Advice on neuroelectrophysiology and nociception

Honorary Research Fellow, University College London 2007–2008

Visiting Research Fellow, University College London, Institute of Neurology 2007–2008

Visiting Fellow, Pain Management Research Institute (PMRI), University of Sydney 2006–2007

Three-month sabbatical on a competitive award from the Royal Society in London to work with Dr Connor and Prof. Macdonald Christie's group at the Pain Management Research Institute lead by Prof. Michael Cousins at Royal North Shore Hospital to examine the neuropharmacology of nerves using whole-cell patch-clamp recordings with particular emphasis on their involvement in migraine mechanisms. These studies provide the first detailed description of the cellular phenotype of sensory neurons innervating structures of the head important for transducing clinically important pain states. This technique may be used with transgenically modified mice

Consultant, Atlas Venture Capital Limited, Grosvenor Street, London 2003

Assisted exploration of some pharmaceutical product offerings by various commercial companies and participation in expert panel discussions

Consultant, Novartis Pharma AG, Gower Place, London 2000

Advice on neuroelectrophysiology and nociception

Consultant, Sigma-Aldrich Research Biochemicals, Natick MA, USA 1997

Conducted original research that launched a new anaesthetic formulation

Lecturer, University of Adelaide, South Australia 1990–1994

Teaching chemistry and biology to 1st year medical, science, and Malaysian–Australian Training and Education Scheme (MATES) students

Research Assistant, Australian Wine Research Institute, University of Adelaide, South Australia

Microbiology Group 1983–1984

Investigated the physiology of *Saccharomyces cerevisiae* important in sparkling wine and Champagne tirage

Flavour Chemistry Group 1982–1983

Characterized and synthesized monoterpene glycosides and ethyl ethers important in wine and brandy spirit

Summer research student, Department of Agricultural Biochemistry, 1981–1982

Waite Agricultural Research Institute, The University of Adelaide

Isolated and characterized novel amino acids (octapines) from rhizobial bacteria important to the Australian fruit industry

POSTGRADUATE EDUCATION & PROFESSIONAL DEVELOPMENT

Building World-Class Academic Journals (Thompson Reuters Seminar)	Information Technology Services Center, Chiang Mai University	2014
UCSF Scientific writing course (Mimi Zeiger)	Cardiovascular Research Institute, University of California, San Francisco, spring 2012	2012
UCSF workshops and online training	<i>including</i> Confidence and optimism in leadership, NIH grant writing, Strategies for leading a productive research team, Negotiating skills, Hazardous materials management and use, Laboratory safety, Health Insurance Portability and Accountability Act (HIPAA)	2007–2012
Intellectual property law and FDA Regulatory issues for Life Scientists	Center for BioEntrepreneurship, University of California, San Francisco	2008
Immunology and Protein Chemistry, PhD, University of Adelaide	Supervision Prof. Antonio Ferrante, PhD, MRCPATH; Prof. Don Robertson, MB, CHB, MD, FRACP	1990–1998
	<ul style="list-style-type: none"> • Thesis: <i>Human retroplacental serum polyamine oxidases: purification and characterization</i> • Immunology, biochemistry, inflammation, cell biology, enzymology, monoclonal antibody production, protein chemistry and purification, peptide chemistry 	
Biochemistry and Cell Biology, MAgSc, University of Adelaide	Supervision Prof. Alan Kerr, AO, PhD, FAA, FRS; Prof. George Maxwell, MB, CHB, MD, FRCP, FRACP	1988–1990
	<ul style="list-style-type: none"> • Biological properties and purification and of polyamine oxidases • Biochemistry, immunology, parasitology, mammalian cell biology 	

LICENCES, CERTIFICATION

Institute for Animals for Scientific Purposes Development (IAD) National Research Council of Thailand (NRCT) License for Animals for Scientific Purpose (U1-03126-2559)	2016
UCSF Institutional Animal Care and Use Committee (IACUC) Basic Regulatory and Ethical Requirement (BRER) I & II	2007–2012
Personal Licence endorsed by the Secretary of State issued by the Home Office of the United Kingdom under the Animals (Scientific Procedures) Act 1986	1996
Certificate, Institute of Biology, London. Animal Use Modules 1, 2, 3, & 4 (Small animal veterinary surgery, husbandry, legal issues)	1996
Royal Australian Chemical Institute, Membership (MRACI), Chartered Chemist (CCHEM)	1991

EDUCATION

PhD	Immunology/Protein Chemistry, <i>University of Adelaide</i>	1990–1998
	<ul style="list-style-type: none"> • Thesis: <i>Human retroplacental serum polyamine oxidases: purification and characterization</i> 	
MAgSc	Biochemistry/Cell Biology, <i>University of Adelaide</i> , South Australia	1988–1990
BSc (Hons)	Neurochemistry/Neuroanatomy, <i>Flinders University of South Australia</i> Flinders Medical Research Institute, Centre for Neurosciences	1985–1986
	<ul style="list-style-type: none"> • supervisors Prof. Marcello Costa, MD, FAA; Prof. John Furness, PhD, FAA • Thesis: <i>Characterization of dynorphin-like immunoreactivity in peripheral neurons</i> 	
BSc	Organic Chemistry/Immunology, <i>University of Adelaide</i> , South Australia	1979–1984
Matriculation	<i>Christian Brothers College</i> , Adelaide, South Australia	1974–1978
Sophomore	Math/Biology/English, <i>Princeton High School</i> , New Jersey, USA	1976–1977

HONOURS AND AWARDS

- Alumni Fellow Award—The University of Adelaide, for service to the University 2013
- Outstanding scientific presentation citation—3rd European Headache and Migraine Trust Intl Congress 2012
(supervisor and co-author with recipient Dr Weera Suprongsinchai)
- Storer RJ, Goadsby PJ. 5-HT_{1F} agonists inhibit nociceptive transmission at the trigeminocervical complex. Cited in a review of some of the most exciting platform and poster presentations by Cutrer FM, Smith JH. 15th International Headache Congress: Basic Science Highlights. *Headache Currents*. *Headache* 2012; 52 (5): 851–8.
- Outstanding scientific presentation citation—15th International Headache Congress, Berlin 2011
(supervisor and co-author with recipient Dr Weera Suprongsinchai)
- Outstanding scientific presentation citation—14th International Headache Congress, Philadelphia 2009
- South Australian Business Ambassadors Network (SABAN) appointment 2007
- South Australian universities Alumni Association (UK chapters), Life Membership Award 2007
- The Royal Society, London, International Short Visit Award 2006
- Outstanding scientific presentation award—12th Congress International Headache Society, Kyoto 2005
- Bailieu Research Prize (1991–1993 three awards for outstanding medical research—University of Adelaide)

KEYWORDS/AREAS OF INTEREST

Pain, headache, migraine, trigeminal, brainstem, neuroanatomy, pharmacology, pathophysiology, neuroscience, electrophysiology, microiontophoresis, microinjection, histology, neurochemistry, opioids, peptide neurotransmitters, serotonin, amino acids, ion channels, immunology, biochemistry, cell biology, enzymology, monoclonal antibodies, ELISA, protein chemistry and purification, peptide chemistry, parasitology, polyamines, neurogastroenterology, organic chemistry, heterocyclic chemistry, immunoconjugates, cancer, flavor chemistry, terpenes, glycosides, ethers, microbiology, *Saccharomyces*, virology

PROFESSIONAL ACTIVITIES**Professional Organizations****Memberships**

- Asia-Pacific Association of Medical Journal Editors (APAME), member 2016
- Australian–Thai Chamber of Commerce, Australian Alumni member 2013–2016
- South Australian Business Ambassadors Network (SABAN) 2007–2015
- Australian–American Chamber of Commerce, member 2007–2010
- International Association for the Study of Pain, member 43991 2005–2010
- International Headache Society, member SRUK01 2003–2016
- American Headache Society, member 2009–2013
- Society for Neuroscience (USA), member No. 100008656 2000–2011
- Australian Business in Europe (ABIE) 2000–2006
- Australian and New Zealand Chamber of Commerce (ANZCC) UK 2000–2005
- British Neuroscience Association, member no. 3436 1999–2008
- Private Dining Club (Peterhouse College, University of Cambridge) 1997–2016
- Private Medical-Scientific Journal/Dining Club (University of Adelaide) 1992–1994
- Royal Australian Chemical Institute, member no. 9141 1991–2016
- Flinders University of South Australia Convocation 1986–2016
- Adelaide University Alumni Association—founding membership 1985–2016
- Women's & Children's Hospital, Adelaide, Scientific and Technical Staff Association 1986–1994
- Centre for Neurosciences, Flinders Medical Research Institute 1985–1986
- Service to professional publications** Peer review 2002–2016
- Asian Biomedicine* (more than 800 manuscripts in past 44 months),
- Cephalalgia* (13 manuscripts in past 5 years),
- Brain* (1 manuscript in past 5 years),
- Headache* (2 manuscripts in past 5 years)

University Service*Campus-wide level*

Adelaide University Alumni Association (Thailand Chapter)	Member	2012–2016
Flinders University Alumni Association (UK Chapter)	Director	2005–2007
	Founder, President	2003–2004
Adelaide University Alumni Association (UK Chapter)	<i>Ex-Officio</i> Chairman, Director	2005–2007
	Founder, Chairman	2000–2004
South Australian universities Alumni Association (UK chapter)	Chairman	2004–2005
	<i>Ex-Officio</i> chairman	2005
	Deputy Chairman	2005–2006
University of South Australia Alumni Association (UK Chapter)	Founder, Director	2003–2004

Faculty level

Research Affairs, Chulalongkorn University, Faculty Advisor		2012–2016+
University of Adelaide Science Association, Science Faculty student representative		1980–1986

Departmental level

University of Adelaide Department of Paediatrics, committee board member		1993–1994
Women's and Children's Hospital, Postgraduate Student Association representative		1990–1994

Public Service

Pleydell Management Organization Industrial & Provident Society	Member	2007–2016
	Board	2000–2006
EC1/New Finsbury New Deal for Communities urban regeneration project		
Board member, chairman, community representative		2000–2002
Goodenough College (The London Goodenough Trust for Overseas Graduates)		
Member's representative to the Management Board, Club Committee		1997–2000
Adelaide Alumni UK Limited, Reg. company no. 04245680. (Not For Profit Organization)		
Founding Chairman and company director		2001–2007

Summary of Public Service Activities

As a member of the EC1 New Deal for Communities board I was jointly responsible for obtaining 52 million Pounds Sterling (£) from UK central government for an urban regeneration project in a deprived area of East London and matching this funding with a further £200 million from local authorities and charities for the duration of a 10 year spend in order to create sustainable change in that community.

I set up and managed alumni association chapters for South Australian university alumni in the United Kingdom obtaining the support of the Australian High Commission and Agent General for South Australia in London and the South Australian State Premier. This organization expanded under my direction to include alumni from The University of Adelaide, Flinders University of South Australia, University of South Australia, and the Carnegie Mellon University's H. John Heinz III School of Public Policy and Management in Adelaide. The association continues to thrive after handover to subsequent directors, and the appointment of a new South Australian Agent General who lends his support, along with that of the State Premier, to the current chair. Our patron, Baroness Susan Greenfield, is director of The Royal Institution of Great Britain. In 2007 I was awarded life membership of the organization in recognition of my service to the organization, and in 2013 an Alumni Fellow Award from The University of Adelaide, for service to the University.

TEACHING and MENTORING

Since my appointment at Chulalongkorn University in July 2012 I have co-supervised a PhD candidate, 2 Masters candidates, and a VI year medical student, and 4 International Federation of Medical Students Association visiting scholars, by demonstrating and teaching neurophysiological research methods, providing advice on publications and presentations, and informal mentoring.

At UCSF from 2007 to 2012 I have contributed to the co-supervision of a PhD student/Junior Specialist. In 2008 I worked closely with a Junior Specialist, assisted with her appointment and recruitment to UCSF, demonstrating and teaching neurophysiological research methods, and providing informal mentoring, continuing the collaboration in 2009–13. In 2009 I worked with two Junior Specialists, demonstrating and

teaching neurophysiological research methods, providing advice on publications and presentations, and informal mentoring. In 2009 I also assisted with the recruitment of a postdoctoral scholar from Chulalongkorn University, Thailand, continuing the collaboration in 2010–12 I have assisted, mentored, and supervised research by the postdoctoral scholar, demonstrating and teaching neurophysiological research methods, providing advice on publications and presentations, and informal mentoring. Informal teaching has included advice to and teaching of a technician, students, and postdoctoral scholars in the UCSF headache research group. In 2012 I collaborated with a second postdoctoral scholar, demonstrating and teaching neurophysiological research methods, providing advice on publications and presentations, and informal mentoring.

In the United Kingdom I was co-supervisor with my head of department, Professor Peter Goadsby, of 4 PhD students and an MBBS summer student providing research advice and mentoring. Informal teaching has included teaching of chemistry and immunohistochemistry to a laboratory technician and mentoring of laboratory group members. I was also a private tutor to a high school student (Long Road School, Cambridge; subsequently at the University of Dundee, UK), an advanced nursing studies Masters student (King's College London, now an MD student New York University), and provided mentoring and thesis guidance and advice to a Masters student (London Metropolitan University).

During my PhD candidature in Adelaide I assisted in the training and supervision of 3 technicians and a BSc(Hons)–MBBS student. I worked as a Lecturer in classes for first year chemistry and biology students in medical, science, and engineering streams. Assisted the Malaysian–Australian Training and Education Scheme (MATES) program, a bridging course for students from Malaysia who were enrolling in a medical degree (MBBS) at The University of Adelaide.

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS AND GRANTS

Current

1. Ratchadaphiseksomphot Fund Type 2 (2557-090) (Principle Investigator) Improving headache treatment through the neurophysiological and pharmacological study of headpain.
Project code: **RA57/094** 199,716 Thai baht/2 y
September 2014–September 2016
2. Ratchadaphiseksomphot Endowment Fund 2013 Strategic depth research: Consolidated Research Cluster 7 (Principle Investigator) Serotonin-1F-receptor agonists in a model of migraine Health Cluster project code **CU-56-394-HR** 400,000 Thai baht/2 y
July 2014–July 2016

Past

1. Sandler Funding with Professor Peter J Goadsby about US \$2M
2. The Royal Society, (London, UK) short visit award (Principle Investigator) 01/10/06–31/01/2007
Neuropharmacology of craniovascular-intracranial nociceptive neurotransmission £4882 direct/y 1
3. Industry 04/01/2004–04/30/2007
Amgen Inc., Thousand Oaks, CA, USA £45,000 direct/y 1
Educational grant for study of large conductance Ca^{+2} -activated K^{+} (maxi, BK_{Ca}) channels in craniovascular nociceptive pathways" (with Professor P J Goadsby—principal investigator) £95,000 direct/y 1–2
4. Industry 2003–2004
Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA £127,435 direct/y 1
Fundamentals of molecular disease £127,435 direct/y 1–2
5. Industry 2002–2003
R W Johnson Pharmaceutical Research Institute, Raritan, NJ, USA £106,060 direct/y 1
Project 1. A study of the possible mechanisms of action of topiramate in the prevention of acute migraine attacks (with Professor P J Goadsby – principal investigator)
6. Industry 2000–2002
Boehringer Ingelheim Pharma KG, Biberach, Germany £40,000 direct/y 1

A study of the role of calcitonin gene-related peptide (CGRP) in trigeminovascular nociceptive transmission (with Professor P J Goadsby – principal investigator)	£72,495 direct/y 1–2
7. Industry	1998–2000
GlaxoWellcome (later GlaxoSmithKline), Stevenage, UK	£50,000 direct/y 1
Mechanistic studies on putative migraine therapies—extension (with Professor P J Goadsby – principal investigator)	£127,400 direct/y 1–3
8. Industry	1995–1997
Glaxo Research & Development Ltd. (GlaxoWellcome plc.)	£50,000 direct/y 1
Mechanistic studies on putative migraine therapies (with Dr Peter J Goadsby—principal investigator)	
9. Industry	1995–1996
Wellcome Australia Ltd. (later GlaxoWellcome)	AU\$58,426 direct/y 1
Neurophysiology and pharmacology of craniovascular nociception (with Dr Peter Goadsby—principle investigator)	AU\$131,520 direct/y 1–2 £150,400 direct/y 2–3
10. Anticancer Foundation of South Australia, University of Adelaide	1986–1987 AU\$20,000 direct/y 1
11–20. Named person on more than 10 research grants (1988–1994) and scholarships either individually (7), and in association with supervisors (3), worth more than AU\$300,957	AU\$181,780 direct/y 1–9

Travel Grants (1) USA 2007–present
 UCSF Academic Senate Travel Awards (invited presentation scientific workshop 2008, Florida;
 International Headache Society Congress 2009, Philadelphia; BIT Life Sciences 2010, Singapore;
 International Headache Society Congress 2011, Berlin) of US\$1830

Travel Grants (2) UK 1996–2005
 Eleven grants with a total value of over £14,393 attracted from GlaxoWellcome UK Ltd,
 GlaxoSmithKline, Boehringer-Ingelheim Pharma KG, Pharmacia, Zeneca Pharmaceuticals PSD,
 Johnson & Johnson PRD, Amgen Inc., The Institute of Neurology (Queen Square), and The Royal
 Society (UK), to present research at international meetings

Travel Grants (3) Australia 1988–1995
 Seven grants with a total value of approximately AUD5800 from Janssen-Cilag, Rhône-Poulenc Rorer,
 Roche Products, Reckitt & Coleman Pharmaceuticals, Eli Lilly Australia, Sandoz, Tosoh Cooperation
 (Japan), Fermchem (Australia), Women's and Children's Hospital (Adelaide), The University of
 Adelaide, and Nagoya University (Japan) for presentation of research at International Conferences

PEER-REVIEWED PUBLICATIONS IN INTERNATIONAL JOURNALS

Total citations: at least 1005 to date (source: Google Scholar).

1. Pozo-Rosich P*, Storer RJ*, Charbit AR, Goadsby PJ. Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. *Cephalalgia* 0(0) 1–10, Mar 2015. DOI: 10.1177/0333102415576723 [Epub ahead of print]. PMID: 25792688. Impact factor: 4.891. Times cited: 1. *equal first author contributions
2. Storer RJ, Suprongsinchai W, Srikiatkachorn A. Animal models of chronic migraine. *Curr Pain Headache Rep.* 19(1):467, Jan 2015. DOI: 10.1007/s11916-014-0467-7. PMID: 25416460. Impact factor: 2.250. Times cited: 2.
3. Srikiatkachorn A, Maneesri le Grand S, Supornsilpchai W, Storer RJ. Pathophysiology of medication-overuse headache—an update. *Headache* 54: 204–210, Jan 2014; Epub 2013 Oct 3. DOI: 10.1111/head.12224. PMID: 24117004. Impact factor: 2.937. Times cited: 13.
4. Storer RJ, Goadsby PJ. Topiramate is likely to have an effective locus of action outside of the trigeminocervical complex. *Cephalalgia* 33; 291–300, April 2013; Epub 2013 Jan 11. DOI: 10.1177/0333102412472069. PMID: 23314783. Impact factor: 4.265. Times cited: 4.
5. Storer RJ, Immke DC, Yin R, Goadsby PJ. Large conductance calcium-activated potassium channels (BK_{Ca}) modulate trigeminovascular nociceptive transmission. *Cephalalgia* 29; 1242–1258, Dec 2009. DOI:

- 10.1111/j.1468-2982.2009.01849.x. PMID: 19911462. Impact factor: 4.265. Times cited: 14.
6. Bergerot A, Storer RJ, Goadsby PJ. Dopamine inhibits trigeminovascular transmission in the rat. *Ann Neurol*. 61(3): 251–262, March 2007. DOI: 10.1002/ana.21077. PMID: 17387726. Impact factor: 10.746. Times cited: 57.
 7. Shields KG, Storer RJ, Akerman S, Goadsby PJ. Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat. *Neuroscience* 135(1): 203–212, 2005. DOI: 10.1016/j.neuroscience.2004.08.054. PMID: 16084658. Impact factor: 3.480*. Times cited: 28.
 8. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. *Cephalalgia* 24(12): 1049–1056, Dec 2004. DOI: 10.1111/j.1468-2982.2004.00767.x. PMID: 15566419. Impact factor: 4.265. Times cited: 81.
 9. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. *Br J Pharmacol*. 142(7): 1171–1181, Aug 2004. DOI: 10.1038/sj.bjp.0705807. PMID: 15237097. Impact factor: 4.925. Times cited: 189.
 10. Storer RJ, Akerman S, Shields, KG, Goadsby PJ. GABA_A receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil. *Brain Res*. 1013(2): 188–193, July 2004. DOI: 10.1016/j.brainres.2004.03.068. PMID: 15193528. Impact factor: 2.665*. Times cited: 26.
 11. Storer RJ, Akerman S, Goadsby PJ. Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex. *Br J Pharmacol*. 138(2): 317–324, Jan 2003. DOI: 10.1038/sj.bjp.0705034. PMID: 12540522. Impact factor: 4.925. Times cited: 13.
 12. Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. *Brain* 125(6): 1392–1401, June 2002. DOI: 10.1093/brain/awf141. PMID: 12023327. Impact factor: 9.603. Times cited: 77.
 13. Goadsby PJ, Akerman S, Storer RJ. Evidence for postjunctional serotonin (5-HT₁) receptors in the trigeminocervical complex. *Ann Neurol*. 50(6): 804–807, Dec 2001. DOI: 10.1002/ana.10066. PMID: 11761480. Impact factor: 10.746. Times cited: 30.
 14. Storer RJ, Akerman S, Goadsby PJ. GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. *Br J Pharmacol*. 134(4): 896–904, Oct 2001. DOI: 10.1038/sj.bjp.0704325. PMID: 11606331. Impact factor: 4.925. Times cited: 30.
 15. Storer RJ, Akerman S, Connor HE, Goadsby PJ. 4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5HT_{1B/1D}) agonist doses. *Neuropharmacology* 40(7): 911–917, June 2001. DOI: 10.1016/S0028-3908(01)00014-4. PMID: 11378161. Impact factor: 3.737*. Times cited: 16.
 16. Lambert GA, Michalick J, Storer RJ, Zagami AS. Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. *Cephalalgia* 19(7): 631–638, Sept 1999. DOI: 10.1046/j.1468-2982.1999.019007631.x. PMID: 10524656. Impact factor: 4.265. Times cited: 47.
 17. Kaube H, Knight YE, Storer RJ, Hoskin KL, May A, Goadsby PJ. Vasodilator agents and supracollicular transection fail to inhibit cortical spreading depression in the cat. *Cephalalgia* 19 (6): 592–597, July 1999. DOI: 10.1046/j.1468-2982.1999.019006592.x. PMID: 10448547. Impact factor: 4.265*. Times cited: 19.
 18. Storer RJ, Goadsby PJ. Trigemino-vascular nociceptive transmission involves *N*-methyl-D-aspartate and non-*N*-methyl-D-aspartate glutamate receptors. *Neuroscience* 90(4): 1371–1379, 1998. DOI: 10.1016/S0306-4522(98)00536-3. PMID: 10338304. Impact factor: 3.480*. Times cited: 95.
 19. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)_{1B/1D} agonists inhibits trigeminal cell firing in the cat. *Brain* 120(12): 2171–2177, Dec 1997. DOI: 10.1093/brain/120.12.2171. PMID: 9448572. Impact factor: 9.603. Times cited: 115.
 20. Storer RJ, Butler P, Hoskin KL, Goadsby PJ. A simple method, using 2-hydroxypropyl- β -cyclodextrin, of administering α -chloralose at room temperature. *J Neurosci Meth*. 77(1): 49–53, Nov 1997. DOI: 10.1016/S0165-0270(97)00110-6. PMID: 9402556. Impact factor: 2.262*. Times cited: 42.
 21. Ferrante A, Storer RJ, Cleland L. Polyamine oxidase activity in rheumatoid arthritis synovial fluid. *Clin Exp Immunol*. 80(3): 373–375, June 1990. PMID: 2372986. Impact factor: 3.134. Times cited: 8.

22. Monk P, Storer RJ. The kinetics of yeast growth and sugar utilization in tirage: the influence of different methods of starter culture preparation and inoculation methods. *Am J Enol Viticult.* 37: 72–6, 1986. Impact factor: 2.568*. Times cited: 12.

Impact factors: Thompson Reuters ISI Web of Knowledge JCR 2010 (*indicates 5-year). Citations: Google Scholar, Scopus, Web of Science 2014.

SUBMITTED

23. Suprongsinchai W, Storer RJ, Hoffmann J, Andreou AP, Akerman S, Goadsby PJ. GABA_A receptors in the nucleus raphe magnus modulate trigeminal cell firing responsive to activation of responsive to activation of craniovascular and perivascular dural afferents. *submitted to Cephalalgia*, 2016
24. Storer RJ*, Hoffmann J*, Park J, Andreou A, Goadsby PJ. Weak *N*-methyl-D-aspartate channel blockers inhibit nociceptive traffic in the trigeminocervical complex. *submitted to Journal of Neuroscience*, 2016
*equal first author contributions

OTHER CREATIVE WORKS

1. Suprongsinchai W, Storer RJ. c-Fos: a neural activity marker for craniofacial pain research. *Chulalongkorn University Dental Journal.* 2015;38:77-92 (peer-reviewed local journal)
2. (Storer RJ*) Asian Biomedicine—Guide for Authors 2015. *Asian Biomedicine* 2015; 9(1): 107–130. (*no authors listed) DOI: 10.5372/1905-7415.0901.362
3. (Storer RJ*) A new Guide for Authors: a clearer path to publication. *Asian Biomedicine* 2015; 9(1): 1–5. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0901.362
4. Celentano DD, Sherman SG, Storer RJ. Identifying and quantifying methamphetamine in hair samples. *Asian Biomedicine* 2014; 8(4): 441–443. [Editorial] DOI: 10.5372/1905-7415.0804.312
5. (Storer RJ* and Wilde H) The face veil or niqab and physical performance. *Asian Biomedicine* 2014; 8(3): 301. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0803.293
6. (Storer RJ* and Wilde H) Stem cells and medical tourism. *Asian Biomedicine* 2014; 8(1): 1–3. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0801.255
7. (Storer RJ* and Wilde H) Breaking the species barrier. *Asian Biomedicine* 2013; 7(6): 731–733. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0706.234
8. (Storer RJ* and Chitr Sitthi-amorn) Chronic viral hepatitis: a need for a comprehensive approach. *Asian Biomedicine* 2013; 7(5): 597-598. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0705.217
9. (Storer RJ* and Wilde H) Shifting landscape of dengue infections. *Asian Biomedicine* 2013; 7(4): 461–462. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0704.200
10. (Storer RJ* and Wilde H) Surgical challenges in a resource poor setting after decades of war and genocide. *Asian Biomedicine* 2013; 7(3): 299–300. [Editorial] (*no authors listed) DOI: 10.5372/1905-7415.0703.179
11. Storer RJ, Goadsby PJ. Research report to Amgen 2007
12. Storer RJ, Goadsby PJ. Research report to Amgen 2006
13. Storer RJ, Goadsby PJ. Research report to Johnson & Johnson 2004
14. Storer RJ, Goadsby PJ. Research report to Boehringer Ingelheim Pharma KG 2003
15. Storer RJ, Goadsby PJ. Research report to GlaxoWellcome 2001
16. Storer RJ, Williams M, Roediger A. Memorandum & Articles of Adelaide Alumni UK Limited Company, Incorporated July 2001.
17. New Finsbury New Deal Interim Board. Delivery Plan. p. 1–106. 2001.
18. New Finsbury New Deal Interim Board, Islington Council, Renasi. Master Plan Framework. 2001.
19. Storer RJ. Anesthesia using α -chloralose as a pre-formed 2-hydroxypropyl- β -cyclodextrin complex. *Neurotransmissions* 15(3):16–19, 1999. Sigma-Aldrich application note. Times cited 3.

20. Storer RJ. Human retroplacental serum polyamine oxidases (PhD Thesis). The University of Adelaide, South Australia, 1998. <http://hdl.handle.net/2440/21600>
<http://digital.library.adelaide.edu.au/theses/09PH/09phs8841.pdf>
21. Storer RJ, Ferrante A. Radiochemical assay of diamine oxidase. *Methods Mol Biol.* 79: 91–95, 1998. PMID: 9463822. Times cited 6.
22. Storer RJ, Ferrante A. Hydrogen peroxide assay for amine oxidase activity. *Methods Mol Biol.* 79: 81–90, 1998. PMID: 9463821. Times cited 7.
23. Storer RJ, Goadsby PJ. Research report to GlaxoWellcome 1997
24. Storer RJ, Ferrante A, Bates DJ, Zola H, Morgan DML. Retroplacental polyamine oxidase: antimicrobial, antiinflammatory, antitumor and immunosuppressive properties; further characterization. In: Tomoda Y, Mizutani S, Narita O, and Klopper A, editors. *Placental and Endometrial Proteins: Basic and Clinical Aspects*. Utrecht: VSP Science Press; 1988. p. 349–52. Times cited 2.
25. Storer RJ. Characterization of dynorphin-like immunoreactivity in peripheral neurons (BSc Honours Thesis). Flinders University, Adelaide, South Australia, 1985.

ABSTRACTS

1. Storer RJ, Pakinsee S, Wilde H, Jacquet A, Nuchprayoon I, Khovidhunkit W, Hurst C, Sitthi-amorn C. Asian Biomedicine: research, reviews, and news. Asia-Pacific Association of Medical Journal Editors 2016; August 27–28, 2016, Bangkok, Thailand.
2. Suprongsinchai W, Storer RJ, Hoffman J, Andreou AP, Akerman S, Goadsby PJ. GABA_A receptors in the nucleus raphe magnus modulate trigeminal cell firing responsive to activation of craniovascular and dura mater afferents. 3rd European Headache and Migraine Trust International Congress; 20–23 September 2012, London, UK. *The Journal of Headache and Pain*, 14 (Supplement 1), February 2013, P67. Impact Factor: 2.427 (2011).
3. Hoffman J, Park JW, Storer RJ, Goadsby PJ. Magnesium and memantine do not inhibit nociceptive neuronal activity in the trigeminocervical complex of the rat. 3rd European Headache and Migraine Trust International Congress; 20–23 September 2012, London, UK. *The Journal of Headache and Pain*, 14 (Supplement 1), February 2013, P71. Impact Factor: 2.427 (2011). Times cited: 1.
4. Suprongsinchai W, Storer RJ, Hoffman J, Andreou AP, Akerman S, Goadsby PJ. GABA_A receptors in the nucleus raphe magnus modulate trigeminal cell firing responsive to activation of craniovascular and dura mater afferents. 54th Annual Scientific Meeting of the American Headache Society; 2–5 June 21–24, 2012, Los Angeles, CA, USA. *Headache*, 52: 903–904, 2012. Impact factor: 2.892. Times cited: 1.
5. Storer RJ, Goadsby PJ. 5-HT_{1F} agonists inhibit nociceptive transmission at the trigeminocervical complex; 15th Congress of the International Headache Society; June 23–26, 2011, Berlin. *Cephalalgia* 31 (Suppl 1): 9–10, July 2011. Impact factor 4.265. Times cited: 3. (Cited in a review of some of the most exciting platform and poster presentations of the meeting by Cutrer FM, Smith JH. 15th International Headache Congress: Basic Science Highlights. *Headache Currents*. *Headache* May 2012; 52 (5): 851–8.)
6. Suprongsinchai W, Storer RJ, Hoffmann J, Andreou AP, Goadsby PJ. Microinjection of lidocaine in nucleus raphe magnus increases stimulus-evoked cell firing in the trigeminocervical complex. 15th Congress of the International Headache Society; June 23–26, 2011, Berlin. *Cephalalgia* 31 (Suppl 1): 107–107, July 2011. Impact factor 4.265. Times cited: 1.
7. Suprongsinchai W, Storer RJ, Hoffman J, Andreou AP, Goadsby PJ. The effects of lidocaine microinjection in nucleus raphe magnus on trigeminal cell firing. 53rd Annual Scientific Meeting of the American Headache Society; June 2–5, 2011, Washington, DC, USA. *Headache* 51 (Suppl. s1): 53–53, June 2011. Impact factor: 2.892
8. Storer RJ, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in headache. BIT Life Sciences 1st Annual World NeuroTalk Congress, June 25–28, 2010, Singapore. (Invited speaker, session chair Track 3-9: Neuropathic pains, mechanism and advances in headache, p. 230).
9. Storer RJ, Pozo-Rosich P, Goadsby PJ. Calcitonin gene-related peptide (CGRP) and its receptor antagonists BIBN4096BS (olcegepant) and CGRP(8–37) can modulate neuronal activity of the trigeminocervical complex of the rat when microinjected into the ventrolateral periaqueductal gray. 14th Congress of the

- International Headache Society; 10–13 September 2009, Philadelphia, PA, USA. *Cephalalgia* 29 (Suppl. 1): 4–4, October 2009. Impact factor: 4.265. Times cited: 3.
10. Storer RJ, Goadsby PJ. Specific modulators of NR2B-subunit-containing *N*-methyl-D-aspartate receptor channel complexes, including agmatine and Ro 25–6981, inhibit nociceptive traffic in the trigeminocervical complex of the rat. 14th Congress of the International Headache Society; 10–13 September 2009, Philadelphia, PA, USA. *Cephalalgia* 29 (Suppl. 1): 135–135, October 2009. Impact factor: 4.265.
 11. Storer RJ, Goadsby PJ. *N*-Methyl-D-aspartate receptor channel complex blockers including memantine and magnesium inhibit nociceptive traffic in the trigeminocervical complex of the rat. 14th Congress of the International Headache Society; 10–13 September 2009, Philadelphia, PA, USA. *Cephalalgia* 29 (Suppl. 1): 135–135, October 2009. Impact factor: 4.265. Times cited 6.
 12. Storer RJ, Pozo-Rosich P, Goadsby PJ. El péptido relacionado con el gen de la calcitonina (CGRP) y los antagonistas de su receptor BIBN4096BS (olcegepant) y CGRP(8-37) modulan la actividad neuronal del complejo trigeminocervical (CTC) en la rata cuando son microinyectados en la sustancia gris periacueductal ventrolateral (vIPAG). Comunicaciones de la Sociedad Española de Neurología 2009. *Neurología* 24 (8):558–558, 2009.
 13. Storer RJ, Goadsby PJ. *N*-methyl-D-aspartate receptor mediated neurotransmission in the trigeminocervical complex of the rat is modulated by (R)-2-amino-5-phosphonopentanoate. Society for Neuroscience 38th Annual Meeting; Washington, DC; 15–19 November 2008.
 14. Storer RJ. Neuronal hyperexcitability and headache pathogenesis (invited lecture). Headache Symposium, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 2 July 2008.
 15. Storer RJ. GABA receptor modulation of trigeminovascular nociception in migraine (invited lecture). 16th Annual Workshop on Steroid Hormones and Brain Function; 8–12 April 2007; Key Largo, Florida, USA.
 16. Storer RJ, Pozo-Rosich P, Goadsby PJ. *N*-methyl-D-aspartate receptor mediated neurotransmission in the trigeminocervical complex of the rat is modulated by the glycine site antagonist 7-chlorokynurate. Society for Neuroscience 37th Annual Meeting; San Diego, California, USA; 3–7 November 2007.
 17. Pozo-Rosich P, Storer RJ, Goadsby PJ. Los receptores de glicina modulan la neurotransmisión en el complejo trigeminocervical de la rata. Comunicaciones de la Sociedad Española de Neurología 2007. *Neurología* 22 (9):556–557, 2007.
 18. Storer RJ, Pozo-Rosich P, Goadsby PJ. Glycine receptors modulate neurotransmission in the trigeminocervical complex of the rat. 13th Congress of the International Headache Society; 28 June–1 July 2007; Stockholm, Sweden. *Cephalalgia* 27 (10): 1183–1183, October 2007. Impact factor: 4.265.
 19. Andreou AP, Storer RJ, Holland PR, Goadsby PJ. CNQX inhibits trigeminovascular neurons in the rat: a microiontophoresis study. Abstract 134. Migraine Trust 16th International Symposium; London, United Kingdom; 18–20 September 2006. *Cephalalgia* 26 (11): 1383–1383, November 2006. Impact factor: 4.265. Times cited: 7.
 20. Goadsby PJ, Storer RJ, Bergerot A. Dopamine receptors and the modulation of trigeminocervical complex (TCC) neurons in the rat. S07.002. American Academy of Neurology 58th Annual Meeting, April 1–8, 2006. San Diego, California, USA. *Neurology* 66 (5) Suppl. 2: A69–A69, March 2006. Impact factor: 8.017. Times cited: 3.
 21. Andreou AP, Storer RJ, Goadsby PJ. Modulation of CGRP release in trigeminal structures by the NMDA glutamate receptor. 7th Queen Square Symposium. University College London Institute of Neurology. March 14, 2006.
 22. Storer RJ, Goadsby PJ. Topiramate has a locus of action outside of the trigeminocervical complex. 12th Congress of the International Headache Society; 9–12 October 2005; Kyoto, Japan. *Cephalalgia* 25 (10): 934–934, October 2005. Impact factor: 4.265. Times cited: 8.
 23. Storer RJ, Immke DC, Goadsby PJ. Modulation of nociceptive pathway activity in the trigeminocervical complex by BK_{Ca} channel blockers and NS1619. 12th Congress of the International Headache Society; 9–12 October 2005; Kyoto, Japan. *Cephalalgia* 25 (10): 918–918, October 2005. Impact factor: 4.789*. Times cited: 1.

24. Storer RJ, Goadsby PJ. Acetazolamide inhibits trigeminovascular nociceptive transmission in the cat. 12th Congress of the International Headache Society; 9–12 October 2005; Kyoto, Japan. *Cephalalgia* 25 (10): 934–934, October 2005. Impact factor: 4.265.
25. Bergerot A, Storer RJ, Goadsby PJ. Dopamine inhibits trigeminovascular transmission in the rat. 12th Congress of the International Headache Society; 9–12 October 2005; Kyoto, Japan. *Cephalalgia* 25 (10): 862–862, October 2005. Impact factor: 4.265. Times cited: 2.
26. Storer RJ, Immke D, Goadsby PJ. Modulation of nociceptive pathway activity in the trigeminocervical complex by BK_{Ca} channel blockers and NS1619. *Proceedings of the 11th World Congress on Pain*, IASP Press: Seattle, p.569. Sydney, Australia. 21–26 August 2005.
27. Goadsby PJ, Storer RJ. Topiramate has a locus of action outside of the trigeminocervical complex. American Academy of Neurology 57th Annual Meeting, April 9–16, 2005. Miami, Florida, USA. *Neurology* 64 (Suppl.): A150–A151, March 2005. Impact factor: 8.017
28. Storer RJ, Akerman S, Goadsby PJ. Blockade of calcitonin gene-related peptide (CGRP) receptors in the trigeminocervical complex reduces trigeminovascular nociceptive traffic. XIth Congress of the International Headache Society; 13–16 September 2003; Rome, Italy. *Cephalalgia* 23 (7): 726–726, September 2003. Impact factor: 4.265. Times cited: 4.
29. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. XIth Congress of the International Headache Society; 13–16 September 2003; Rome, Italy. *Cephalalgia* 23 (7): 726–726, September 2003. Impact factor: 4.265. Times cited: 19.
30. Shields, KG, Storer RJ, Akerman S, Goadsby PJ. Post-synaptic high-threshold voltage dependent calcium channels (VDCC) modulate trigeminovascular nociceptive transmission in the Trigemincervical complex (TCC). XIth Congress of the International Headache Society; 13–16 September 2003; Rome, Italy. *Cephalalgia* 23 (7): 726–726, September 2003. Impact factor: 4.265. Times cited: 3.
31. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. American Academy of Neurology 55th Annual Meeting; March 29–April 5, 2003; Honolulu, Hawaii, USA. *Neurology* 60 (Suppl 1): A238–A239, 2003. Impact factor: 7.043.
32. Goadsby PJ, Hoskin KL, Storer RJ, Akerman S, Edvinsson L, Connor HE. Inhibition of trigeminovascular nociceptive transmission by A(1) receptor agonists in the cat. A25. Proceedings of the Association of British Neurologists, University of Oxford, 3–5 April 2002; Oxford, United Kingdom. *Journal of Neurology Neurosurgery and Psychiatry* 73 (2): 218–218, Aug 2002. doi:10.1136/jnnp.73.2.213. Impact factor: 4.791
33. Goadsby PJ, Akerman S, Storer RJ. Triptans can act post-synaptically in the trigeminal nucleus: a microiontophoretic study. 10th Congress of the International Headache Society, 29 June–2 July 2001; New York City, USA. *Cephalalgia* 21 (4): 285–285, May 2001. Impact factor: 4.265.
34. Goadsby PJ, Hoskin KL, Edvinsson L, Storer RJ, Akerman S, Connor HE. Inhibitory effects of adenosine A1 agonists on the cat trigeminovascular system: a new target for anti-migraine drugs? 10th Congress of the International Headache Society, 29 June–2 July 2001; New York City, USA. *Cephalalgia* 21 (4): 352–352, May 2001. Impact factor: 4.265. Times cited: 7.
35. Storer RJ, Akerman S, Goadsby PJ. Opioid receptors modulate nociceptive neurotransmission in the trigeminocervical complex. 10th Congress of the International Headache Society, 29 June–2 July 2001; New York City, USA. *Cephalalgia* 21 (4): 354–354, May 2001. Impact factor: 4.265.
36. Storer RJ, Akerman S, Goadsby PJ. GABA_A receptors modulate nociceptive neurotransmission in the trigeminocervical complex. Headache World 2000 (XXII Migraine Trust International Symposium, Millennial International Headache Society Congress, 5th European Headache Foundation Conference, 1st Global Convention of the World Headache Alliance); 3–7 September 2000; London, United Kingdom. *Cephalalgia* 20: 273.4, 2000. Impact factor: 4.265.
37. Storer RJ, Connor HJ, Goadsby PJ. Microiontophoretic application of 4991W93 inhibits trigeminocervical neurons. In: Titus F, Láinez MJA, editors. Proceedings of the 9th Congress of the International Headache Society; 22–26 June 1999; Barcelona, Spain. *Cephalalgia* 19 (4): 314–314, May 1999. Impact factor: 4.265. Times cited: 6.

38. Storer RJ, Goadsby, PJ. Excitatory amino acid transmission in the trigeminocervical complex: a role in migraine? In: Kennard C, Goadsby PJ, Rush A, Steiner, TJ, editors. *Proceedings of the 12th Migraine Trust International Symposium*, p. 30–31; London, United Kingdom; 1–4 September 1998.
39. Storer RJ, Goadsby PJ. Direct evidence using microiontophoresis that neurons of the caudal trigeminal nucleus contain 5HT_{1B/D} receptors. A241. In: Ferrari M, Schoenen J, editors. *Proceedings of the 8th Congress of the International Headache Society*, 10–14 June 1997; Amsterdam, The Netherlands. *Cephalalgia* 17 (3): 230–231, May 1997. Impact factor: 4.265. Times cited 2.
40. Lambert GA, Storer RJ. Effect of spreading cortical depression on activity of trigeminovascular sensory neurons. In: Welch KMA, editor. *Proceedings of the 7th International Headache Congress*; 16–20 September 1995; Toronto, Canada. *Cephalalgia* 15 (Suppl. 14): 112–112, September 1995. Impact factor: 4.265.
41. Storer RJ, Ferrante A, Morgan DML. Immunoaffinity purification of human retroplacental polyamine oxidase. In: Yu PH, Tipton KF, Boulton AA, editors. *Proceedings of the 6th Amine Oxidase Workshop and 5th Trace Amine Conference*, C06; IUPHAR Satellite; Saskatchewan, Canada; 31 July–3 Aug 1994.
42. Storer RJ, Ferrante A. Purification of Retroplacental Polyamine Oxidizing Enzymes. In: Taki I, Soma H, editors. *Proceedings of the International Conference on Placenta* (Kokusai Taiban Godokaigi) p. 74. Tokyo, Japan; 1–3 October 1990.
43. Storer RJ, Ferrante A, Bates DJ, Morgan DML. Retroplacental polyamine oxidases: Antimicrobial, antiinflammatory, antitumor and immunosuppressive properties. In: Tomoda Y, Mizutani S, Narita O, and Klopper A, editors. *Proceedings of the 6th International Congress on Placental and Endometrial Proteins*, p. 149; Nagoya, Japan; 1–3 December 1987.
44. Storer RJ, Murphy R, Furness JB, Costa M. Characterization of dynorphin-like immunoreactivity in intestinal nerves. In: McCance I, Luff A, editors. *Proceedings of the Australian Physiological and Pharmacological Society*; 26–28 August 1985; Sydney, Australia. *Aust Physiol Pharm Soc Proc* 16: 93, 1985.

Patents

Robin James Storer has a postgraduate certificate in Intellectual Property Law and FDA Regulatory Issues for Life Scientists (2008) from the Center for BioEntrepreneurship, University of California, San Francisco, USA.

Work has resulted in patents of antibodies to polyamine oxidases (also known as Vascular Adhesion Protein-1 [VAP-1]) for the Finish biotechnology company, BioTie Therapies Corp., Turku, which focuses on inflammatory diseases.

http://www.biotie.com/product-portfolio/vap1-antibody.aspx?sc_lang=en [accessed 2016/01/26]

Robin James Storer has conducted preclinical research and development of, and proof of concept studies for a number of pharmaceutical FDA approved antimigraine drugs in collaboration with pharmaceutical companies in the UK, Germany, and USA.

1. Sumatriptan, Glaxo Research & Development Ltd. (GlaxoWellcome plc, GlaxoSmithKline)
2. Zolmitriptan (311C90) Astra-Zeneca/Wellcome (UK)
3. 4991W93, GlaxoWellcome, Stevenage, UK (GSK)
4. GR79236, GlaxoWellcome, Stevenage, UK (GSK)
5. α -Chloralose:2-hydroxypropyl- β -cyclodextrin complex (veterinary anaesthetic; Sigma-Aldrich, MA, USA)
6. Olcegepant (BIBN4096BS) Boehringer Ingelheim Pharma KG, Biberach, Germany
7. Topiramate, R W Johnson Pharmaceutical Research Institute (Johnson & Johnson) Raritan, NJ, USA
9. BKCa channel openers, Amgen, Thousand Oaks, CA, USA
10. (confidential)